Adcances in CpG oligodeoxynucleotides in the cancer immunotherapy
10.3781/j.issn.1000-7431.2010.04.016
- VernacularTitle:CpG寡聚脱氧核苷酸在肿瘤免疫治疗中的应用进展
- Author:
Binbin MA
;
Peijun ZHOU
;
Da XU
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Immunotherapy;
Drug therapy,combination;
Toll-like receptors;
CpG oligodeoxynucleotide
- From:
Tumor
2010;(4):347-351
- CountryChina
- Language:Chinese
-
Abstract:
CpG oligodeoxynucleotides (ODN) have potent immunostimulatory effects and can enhance the anti-cancer activity of cancer treatments. CpG ODN directly induced the activation and maturation of plasmacytoid dendritic cells, stimulated the secretion of Th1-type cytokines, and enhanced the differentiation of B cells into antibody-secreting plasma cells. CpG oligodeoxynucleotides as vaccine adjuvants can enhance both the humoral and cellular responses to antigens in some clinical trails. CpG ODN was applied in several clinical trials as an adjuvant of tumor vaccine. CpG ODN alone had anti-tumor activity and had synergistic effects with other anti-tumor therapies including monoclonal antibodies, chemotherapy, radiotherapy, cytokines, etc. Compared with standard regimen, in the phase Ⅲ clinical trial CpG ODN did not prolong the median survival time and induced severe adverse reaction in the treatment of ⅢB-Ⅳ stage non-small cell lung cancer. But CpG ODN had definite anti-cancer activity in other clinical trials. The safety and efficacy of CpG ODN in anti-tumor therapy needs to be further verified in clinic.
